Back to Search Start Over

The Pharmacokinetics and Safety of a Fixed-Dose Combination of Acetylsalicylic Acid and Clopidogrel Compared With the Concurrent Administration of Acetylsalicylic Acid and Clopidogrel in Healthy Subjects: A Randomized, Open-Label, 2-Sequence, 2-Period, Single-Dose Crossover Study.

Authors :
Jin Ah Jung
Tae-Eun Kim
Jung-Ryul Kim
Min-Ji Kim
Wooseong Huh
Kyung-Mi Park
Soo-Youn Lee
Jae-Wook Ko
Source :
Clinical Therapeutics. 2013, Vol. 35 Issue 7, p985-994. 10p.
Publication Year :
2013

Abstract

Background Dual antiplatelet therapy with clopidogrel plus acetylsalicylic acid (ASA) is used for the treatment of acute coronary syndrome. A combined formulation of ASA and clopidogrel has been developed to provide dosing convenience and improve adherence. Objective This study was designed to compare the pharmacokinetic properties and safety profile of a fixed-dose combination formulation of ASA and clopidogrel with concurrent administration of each agent in healthy male Korean volunteers. Methods This single-dose, randomized, open-label, 2-period crossover study was conducted in 64 healthy Korean volunteers. Equal numbers of eligible participants were randomly assigned to receive either the fixed-dose combination of ASA 100 mg and clopidogrel 75 mg or the free combination of each agent followed by a 7-day washout period and then administration of the alternate formulation. Serial blood samples were collected immediately before and after dosing for 24 hours. The safety profile was evaluated by using adverse events (AEs), which were assessed by physical examination, vital signs, ECGs, clinical laboratory tests, and interviews. The 2 formulations were considered to be bioequivalent if the 90% CIs for the log-transformed Cmax and AUC0--last values were within the predetermined range of 0.8 to 1.25. Results Sixty-four volunteers (mean [SD] age, 27.51 [8.15] years; weight, 68.55 [7.86] kg; height, 173.80 [5.94] cm) were enrolled, and 63 completed the study. For ASA, the 90% CIs for the geometric mean ratios of Cmax and AUC0--last were 0.9483 to 1.1717 and 0.9946 to 1.1020, respectively. For salicylic acid, the 90% CIs were 0.9614 to 1.0396 for Cmax and 0.9778 to 1.0163 for AUC0--last. For clopidogrel, the 90% CIs were 0.9809 to 1.2562 for Cmax and 0.9674 to 1.2073 for AUC0--last. Six of the 20 AEs reported were drug related: decreased hemoglobin levels (n = 2), fever (n = 1), and headache (n = 1) with the test formulation and increased alanine aminotransferase levels (n = 1) and dyspepsia (n = 1) with the reference formulation. All of the drug-related AEs were transient and mild in severity. Conclusions The fixed-dose combination of ASA and clopidogrel 100 mg/75 mg did not meet the regulatory criteria for bioequivalence as defined by the Korea Food and Drug Administration. Both formulations were well tolerated in these healthy male Korean subjects. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01492918
Volume :
35
Issue :
7
Database :
Academic Search Index
Journal :
Clinical Therapeutics
Publication Type :
Academic Journal
Accession number :
89370213
Full Text :
https://doi.org/10.1016/j.clinthera.2013.05.015